Haematologica (May 2007)

Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC)

  • Stéphane Vigouroux,
  • Mauricette Michallet,
  • Raphaël Porcher,
  • Michel Attal,
  • Lionel Ades,
  • Marc Bernard,
  • Didier Blaise,
  • Reza Tabrizi,
  • Frédéric Garban,
  • Jill-Patrice Cassuto,
  • Patrice Chevalier,
  • Thierry Facon,
  • Norbert Ifrah,
  • Marc Renaud,
  • Hervé Tilly,
  • Jean-Paul Vernant,
  • Mathieu Kuentz,
  • Jean-Henri Bourhis,
  • Pierre Bordigoni,
  • Eric Deconinck,
  • Bruno Lioure,
  • Gérard Socié,
  • Noël Milpied

DOI
https://doi.org/10.3324/haematol.10924
Journal volume & issue
Vol. 92, no. 5

Abstract

Read online

Background and Objectives High-dose chemotherapy with allogeneic stem cell transplantation (SCT) has proven to be a successful treatment for low-grade lymphoma (LGL), but is associated with considerable transplant-related mortality (TRM). In an effort to reduce toxic mortality while maintaining the graft-versus-leukemia effect, allogeneic SCT has been combined with a reduced-intensity conditioning (RIC) regimen. The aim of this study was to determine the outcome of patients with LGL treated with RIC allogeneic SCT.Design and Methods This retrospective multicenter study included 73 patients with relapsed or refractory LGL allografted after a RIC regimen between 1998 and 2005 whose data were recorded in a French registry.Results Patients received a median of three lines of therapy prior to RIC allogeneic SCT. The most widely used conditioning regimens were fludarabine + busulfan + antithymocyte globulin (n=43) and fludarabine + total body irradiation (n=21). Prior to allografting, patients were in complete response (CR; n=21), partial response (PR; n=33) or had chemoresistant disease (n=19). The median follow-up was 37 months (range, 16 to 77 months). In patients in CR, PR and chemoresistant disease, the 3-year overall survival rates were 66%, 64% and 32%, respectively, while the 3-year event-free survival rates were 66%, 52% and 32%, respectively. The 3-year cumulative incidences of TRM were 32%, 28% and 63%, respectively. The incidence of relapse was 9.6%.Interpretation and Conclusions Although associated with significant TRM, RIC allogeneic SCT in advanced chemosensitive disease leads to long-term survival.